Global Microneedle Flu Vaccine Market to Cross $1.5 Billion by 2029, Driven by Innovative Self-Administered … – Yahoo Finance UK

Company Logo

Global Microneedle Flu Vaccine Market

Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Microneedle Flu Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.

The advent of microneedle technology for flu vaccination presents a transformative approach in the pharmaceutical industry, leading to the noteworthy expansion of the Global Microneedle Flu Vaccine Market. With a standing valuation at USD 1.1 billion in 2023, the market is projected to ascend with a compound annual growth rate (CAGR) of 5.89%, reaching $1.54 billion by 2029.

Microneedle technology stands at the forefront of innovative vaccination methods, offering painless and minimally invasive alternatives to conventional flu shots. This technology is designed to administer vaccines directly into the skin's immune cell-rich areas, potentially eliciting stronger and faster immune responses. The incorporation of self-administered vaccination methods addresses the growing demand for efficient healthcare delivery systems, particularly highlighted by the pandemic's exigencies.

Increasing Acceptability Among Patients

The market's growth is further propelled by the widespread acceptance of microneedle vaccines for their perceived painlessness and user-friendliness. The microneedle patches' self-applicability feature plays a crucial role in mitigating vaccine hesitancy, improving patient compliance, and streamlining healthcare processes. Particularly in regions lacking refrigeration infrastructure, the heat stability of some microneedle vaccine formulations simplifies storage and transportation, making vaccinations more accessible and contributing to global vaccine equity.

Advancements in Vaccine Technology

Recent research and investments in the segment have led to prolific advancements, driving technological innovation across microneedle designs, manufacturing processes, and vaccine formulations. This has been paramount in diversifying the usage of microneedle technology, with applications potentially extending beyond influenza to target diseases like measles, polio, and even COVID-19.

Story continues

Challenging Horizons with Regulatory Complexities

Despite the optimistic outlook on market growth, the pathway is not without its impediments. High initial costs, stringent regulatory approvals, and the demand for standardization pose significant challenges that influence market dynamics. Success in navigating these hurdles depends heavily on the ability of companies to secure substantial investment and successfully pass through stringent regulatory vetting processes.

Solid Microneedles Emerging as the Market Leader

Segmentation insights reveal a notable lead by the Solid Microneedle segment, attributed to ease of use, patient comfort, and the consequent potential for widespread acceptance. Within vaccine types, Trivalent Flu Vaccines hold a dominant market share, spotlighting an area ripe for innovation and market penetration through microneedle technology.

North America Leading Regional Market Growth

In a geographical context, North America spearheads the Global Microneedle Flu Vaccine Market, thanks to its advanced healthcare system, leading-edge research capabilities, and responsive consumer base. These attributes have anchored North America as a pivotal region for the growth and adoption of microneedle flu vaccines.

The Solid Microneedle segment has demonstrated significant growth and is expected to continue its momentum, driven by patient preference and the promise of increased efficacy.

Trivalent Flu Vaccines harness the largest segment in vaccine types, leveraging a well-established market presence to introduce microneedle variants.

Key Attributes

Report Attribute

Details

No. of Pages

185

Forecast Period

2023-2029

Estimated Market Value (USD) in 2023

$1.1 Billion

Forecasted Market Value (USD) by 2029

$1.54 Billion

Compound Annual Growth Rate

5.8%

Regions Covered

Global

A selection of companies mentioned in this report includes, but is not limited to:

Debiotech SA

NanoPass Technologies Limited

Becton, Dickinson and Company

FluGen, Inc.

CosMED Pharmaceuticals Co. Ltd.

Microdermics Inc.

TSRL Inc

Vaxess Technologies

PFIZER, INC.

MERCK & CO. INC.

For more information about this report visit https://www.researchandmarkets.com/r/nakyio

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

Continued here:

Global Microneedle Flu Vaccine Market to Cross $1.5 Billion by 2029, Driven by Innovative Self-Administered ... - Yahoo Finance UK